
Genetic testing is crucial for advanced prostate cancer patients, particularly those with de novo metastases, and emerging treatments like lutetium-PSMA and actinium-PSMA offer promising options for patients who do not respond to conventional therapies.


coremsg

Dr Mohammad Mahmoud discusses key findings from AUA 2024 that will affect his patients with advanced prostate cancer.

AUA 2024: Prostate Cancer Treatment and Testing Updates

genetic-testing-and-emerging-treatments-highlighted-at-aua-2024-for-prostate-cancer-patients


Genetic Testing and Emerging Treatments Highlighted at AUA 2024 for Prostate Cancer Patients
